Recent advances in targeting protein kinases and pseudokinases in cancer biology.

ABSTRACT: Kinases still remain the most favorable members of the druggable genome, and there are an increasing number of kinase inhibitors approved by the FDA to treat a variety of cancers. Here, we summarize recent developments in targeting kinases and pseudokinases with some examples. Targeting the cell cycle machinery garnered significant clinical success, however, a large section of the kinome remains understudied. We also review recent developments in the understanding of pseudokinases and discuss approaches on how to effectively target in cancer.

SUBMITTER: Riegel K 

PROVIDER: S-EPMC9354965 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature